


NDI-091143

Cat. No.:	HY-127111		
CAS No.:	2375840-87-0		
Molecular Formula:	C ₂₀ H ₁₄ ClF ₂ NO ₅ S		
Molecular Weight:	453.84		
Target:	ATP Citrate Lyase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (220.34 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass	Preparing Stock Solutions		
			1 mg	5 mg	10 mg
1 mM			2.2034 mL	11.0171 mL	22.0342 mL
5 mM			0.4407 mL	2.2034 mL	4.4068 mL
10 mM			0.2203 mL	1.1017 mL	2.2034 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (4.58 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.58 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.58 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC₅₀ of 2.1 nM (ADP-Glo assay), a K_i of 7.0 nM and a K_d of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate^[1].

IC₅₀ & Target

IC₅₀: 2.1 nM (human ATP-citrate lyase); K_i: 7.0 nM (human ATP-citrate lyase); K_d: 2.2 nM (human ATP-citrate lyase)^[1]

In Vitro

Thermal shift assays shows that NDI-091143 gives rise to considerable stabilization of both full-length ACLY and the N-

terminal segment. The thermal shift data are consistent with limited proteolysis experiments using full-length ACLY, in which NDI-091143 together with Mg-ATP provided the greatest protection against digestion by chymotrypsin^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Chem Biol Interact. 2022 Sep 26;367:110199.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wei J, et al. An allosteric mechanism for potent inhibition of human ATP-citrate lyase. Nature. 2019 Apr;568(7753):566-570.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA